Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV and hidden health risks: a major study probes the link

NCT ID NCT02382822

Knowledge-focused Sponsor: Susanne Dam Nielsen, MD, DMSc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study compares over 1,500 people living with HIV to a similar group from the general population to see if conditions like heart disease, COPD, and liver disease are more common or develop faster in those with HIV. Using detailed scans and tests, researchers will measure the prevalence of these conditions and explore how HIV-related and non-HIV factors contribute. The goal is to better understand and potentially prevent these serious comorbidities in people with HIV.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study succeeds, it could reveal whether people with HIV face higher risks of heart, lung, and liver diseases, guiding better screening and prevention strategies.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Differences between groups might be due to factors other than HIV, and the findings may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,099 people

The number who actually took part.

Started

Feb 2015

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

HIV infected patients.

Ages

20 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * signed informed consent * HIV infected * aged 20-100 years Exclusion Criteria: * patients that are unable to understand information material Computed tomography (CT): * contraindications to CT and contrast (i.e. pregnancy, renal impairment, allergy to contrast media, allergy or contraindication to beta blocking agent, body weight more than 120kg, evidence of ongoing myocardial ischemia, heart rhythm precluding EKG gating) Spirometry: * relative contraindications to spirometry (i.e. chest, abdominal or eye surgery within the 3 months before baseline spirometry, and known retinal detachment) * allergy or contraindications to salbutamol (i.e. \>110 bpm, or a known uncontrolled cardiac condition (i.e. unstable coronary artery disease, decompensated heart failure) * a respiratory illness with at least two symptoms of breathlessness, cough, wheezing, or increase in sputum production within 6 weeks. MRI: * Implants (e.g. pacemaker, coclea implants, insulin pumps) * Claustrophobia * Pregnancy Liver Biopsy: * Risk of bleeding * Infection in puncture site

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset HIV infectious disease liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD CVD HIV Liver disease

Contacts and locations

Locations

  • Copenhagen University Hospital - Amager and Hvidovre

    Hvidovre, Denmark

  • Copenhagen University Hospital - Rigshospitalet

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.